Cathy Tie left university to found her first biotechnology company at the age of 18. In the 11 years since, she has launched several more. Her first company helped genetic-testing firms to interpret their results; her second provides digital health-care services.
Her latest venture … veers out of the mainstream. Tie, who has called herself Biotech Barbie, sometimes refers to her latest company as the Manhattan Project … now focuses her entrepreneurial ambitions on a controversial goal: altering the genomes of human embryos to prevent genetic disorders.
“We have a duty to patients with incurable, debilitating diseases,” says Tie. “A majority of Americans are in support of this technology.”
Follow the latest news and policy debates on sustainable agriculture, biomedicine, and other ‘disruptive’ innovations. Subscribe to our newsletter.
For years, the gene-editing field has laboured in the shadow of He Jiankui, a Chinese biophysicist who, in 2018, announced that he had edited human embryos to bolster the resulting children’s resistance to HIV.
…
Tie [notes] that methods used to edit genes have evolved considerably since He’s experiments. Newer techniques, such as base editing and another approach called prime editing, offer improved precision compared with conventional CRISPR–Cas9 editing.